The U.S. Food and Drug Administration (FDA) has recently raised concerns regarding the use of Cardinal Health Monoject syringes in conjunction with syringe pumps and patient-controlled analgesia (PCA) pumps. Pending further evaluation, healthcare providers and facilities are strongly advised against utilizing these particular syringes. It is important to note that the Cardinal Health Monoject syringes, which differ in dimensions from the previously branded “Covidien” Monoject syringes, are manufactured by a different contract manufacturer.
The dimensional variances in the Cardinal Health syringes may lead to compatibility issues and potential disruptions in pump performance. These issues include the risk of overdose, underdose, delays in therapy administration, and occlusion alarm delays. In response to these concerns, Cardinal Health has initiated a recall for specific Cardinal Health Monoject single-use Luer-lock tip syringes. The FDA has classified this recall as a Class I recall, indicating the most severe type of recall due to the potential risks involved.
To ensure patient safety, healthcare providers are strongly advised not to use Cardinal Health Monoject syringes with syringe pumps or PCA pumps. However, it is important to highlight that the use of Covidien Monoject syringes with syringe pumps or PCA pumps is still considered safe and can be continued without any concerns.
Cardinal Health, Inc.
Updated on: 07/12/2023
Debt to equity ratio: Strong Sell
Price to earnings ratio: Strong Sell
Price to book ratio: Strong Sell
DCF: Strong Buy
We did not find social sentiment data for this stock
|Analyst / firm||Rating|
Robert W. Baird
Cardinal Health Inc (CAH) Shows Positive Stock Performance and Projected Earnings Growth
On November 20, 2023, Cardinal Health Inc (CAH) opened at $103.05 and traded within a range of $102.99 to $105.79. The total volume of shares traded was 2,086,140. The market capitalization of CAH is $25.5 billion.
CAH has shown positive earnings growth, with a growth rate of 14.54% this year. The next five years are projected to bring even stronger earnings growth, with an estimated growth rate of 17.33%.
In terms of revenue growth, CAH saw a growth rate of 13.04% last year.
The price-to-earnings (P/E) ratio for CAH is 172.6, indicating that the stock is relatively expensive compared to its earnings. The price-to-sales ratio is 0.12, indicating that the stock is undervalued in terms of its sales.
CAH is expected to report its next earnings on February 8, 2024, with an estimated earnings per share (EPS) of $1.57 for the current quarter.
CAH reported annual revenue of $205.0 billion for the last year, with a net profit of $261.0 million. The net profit margin for the company stands at 0.13%.
Cardinal Health Inc operates in the Distribution Services sector and is specifically categorized under Medical Distributors. The company’s corporate headquarters are located in Dublin, Ohio.
In conclusion, CAH has shown positive stock performance on November 20, 2023, with a slight increase in price. The company has experienced growth in earnings and revenue, and analysts expect further growth in the coming years. However, the stock is relatively expensive based on its P/E ratio.
Cardinal Health Inc Stock Price Decreases Slightly on November 20, 2023: Analysts Forecast and Investment Consensus
On November 20, 2023, Cardinal Health Inc (CAH) experienced a slight decrease in its stock price. The 13 analysts who offered 12-month price forecasts for CAH had a median target of $105.00, with a high estimate of $126.00 and a low estimate of $78.70. This median estimate represented a -0.24% decrease from the last price of $105.25.
The consensus among 16 polled investment analysts is to hold stock in Cardinal Health Inc. This rating has remained steady since November.
Investors should consider various factors, including market conditions, industry trends, and company-specific news when making investment decisions.
Cardinal Health Inc reported earnings per share of $1.57 and sales of $56.1 billion for the current quarter. The reporting date for these figures is set for February 8.
Overall, the stock performance of Cardinal Health Inc on November 20, 2023, showed a slight decrease, with the median target price forecasted to be slightly lower than the last price. However, the consensus among investment analysts remains to hold the stock. Investors should closely monitor any updates or news regarding Cardinal Health Inc to make informed investment decisions.